Compared to the dialysis control cohort, samples from patients with non-severe COVID-19 had higher levels of the lectin PRMs M-ficolin (p=0.02) and CL-K1 (p=0.007) and the C3 activation marker C3dg (p=0.02), but lower CL-L1 (p=0.02), MASP-3 (p=0.008) and MAp19 (p=0.008) levels (Figure 1B and Supplementary Table 2). The gene discussed is C3; the disease is COVID-19.